Gujarat Terce Laboratories Limited · BSE:GUJTERC
Gujarat Terce Laboratories — Q2 FY23 Earnings Presentation
11 slides from Gujarat Terce Laboratories's earnings presentation, November 2022
Slide 1: Gujarat Terce Laboratories Limited
GUJARAT TERCE 44 LABORATORIES LIMITED
Slide 2: Disclaimer
Disclaimer This presentation is for informational purposes only and does not constitute an offer or a solicitation to sell or an edition or a solicitation to submit an offer to purchase or subscribe for shares or securities of Gujarat Terce Laboratories Limited or a portion thereof, constitute the b
Slide 3: Company Overview
Company Overview Gujarat Terce has over 3 decades of experience in the Manufacturing and Marketing of branded Generics. Roots of Gujarat Terce Laboratories Limited are entrenched in the founding principles of COMPASSION and EXCELLENCE. Terce has an extensive basket of 50 Brands (125 products) with a
Slide 4: Business Highlights
Business Highlights Figures= % of total sales Figures= % of total sales 100 64 81 79 Q1FY22 36 76 75 70 Acute Segment 63 Other Brands Q2FY22 37 Chronic Segment Precious Brands 50 30 24 56 21 25 19 Q1FY23 44 57 Q2FY23 43 0 Q1FY22 Q2FY22 Q1FY23 Q2FY23 0 25 50 75 As per AICOD Q2FY23 vs Q2FY22 data: Our
Slide 5: Business Highlights- PCPM (Per Capita Per Month)
Business Highlights- PCPM (Per Capita Per Month) 2 1.82 1.75 1.63 1.42 1.5 The expansion in geographies that we did in this FY, has started reflecting in revenues and we will be consistently 1 growing our productivity per medical representative, thus ensuring pathway towards profitability. 0.5 0 Q3F
Slide 6: Business Highlights- Sales of Top Four Brands
Business Highlights- Sales of Top Four Brands Figures in lacs 300 125 118 266 228 100 93 208 204 86 200 75 69 57 117 50 100 25 0 0 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Therapeutic Segment- Anticold Therapeutic Segment- Pain Management Type- Acute Type- Acute
Slide 7: Business Highlights- Sales of Top Four Brands
Business Highlights- Sales of Top Four Brands Figures in lacs 75 79 80 80 67 60 54 53 50 50 40 29 25 25 26 25 20 0 0 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Therapeutic Segment- Nutraceutical Therapeutic Segment- Vitamins ( Nutraceuticals) Type- Acute Type- Chronic
Slide 8: Distribution Network & Region Wise Sales
Distribution Network & Region Wise Sales North 22.3% 17 6 105 139 28 75 75 West 12 1 55.1% 18 Central 22.6% 1 3 1 Stockists/ Region-wise sales distribution(Q2FY23) Distributors
Slide 9: Financial Highlights- Q2 FY23
Financial Highlights- Q2 FY23 Q2FY23 24% -150% -230% YoY growth Op revenue EBIDTA PAT 6mFY23 9.60% -220.36% -183.05% YoY growth Op revenue EBIDTA PAT As per AICOD data, the Q2FY23 growth of IPM (Indian Pharmaceutical Market) is 13%. Gujarat Terce has grown by 24% in Q2FY23. Cash Profit registered by
Slide 10: Q2FY23- Income Statement
Q2FY23- INCOME STATEMENT (Rs. In Lacs) Y-O-Y Q-O-Q Y-O-Y 6 month 6 month Q2 Q1 Q2 6 month Particulars Q2 vs. Q1 Q2 vs. Q2 ended 30-09- ended 30-09- 2022-23 2022-23 2021-22 % Change % Change % Change 2022 2021 (2022 vs 2021) Revenue from Operations 1257.57 941.35 33.59% 1012.63 24% 2,198.92 2,006.32
Slide 11: Thank you.
Thank you. Registered Office: Gujarat Terce Laboratories Limited, 122/2 Ravi estate, Bileshwarpura, Chhatral, T.A.: Kalol, Gandhinagar, Gujarat 382729 Corporate office: D/ 801 - 802 & 1202, The First, Behind Keshavbaug party plot, Near Shivalik High- Street, Vastrapur, Ahmedabad, Gujarat 380015 Inve
Gujarat Terce Laboratories — Q2 FY23 Earnings Presentation on 6ix